^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    MammaPrint®

    Company:
    Agendia
    Related tests:
    1d
    BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Illinois at Chicago | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • EndoPredict®
    |
    azacitidine
    6d
    Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer. (PubMed, Histopathology)
    Short-course preoperative ET induces rapid and reproducible morphological and immunophenotypic changes in ER-positive, HER2-negative breast cancer. Ki67-defined response is associated with genomic risk and PR expression, whereas microenvironmental features appear to have limited predictive value.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 expression • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    8d
    Breast 54: Focused Ultrasound and Gemcitabine in Breast Cancer (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Patrick Dillon, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint®
    |
    gemcitabine
    9d
    LEEWARD: A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors (clinicaltrials.gov)
    P=N/A, N=750, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test • MammaPrint® • EndoPredict®
    14d
    NACAGEP: Gene Expression Profiling to Help Define the Need for Neo-Adjuvant Chemotherapy in HR+, HER- Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=22, Completed, Universitair Ziekenhuis Brussel | Recruiting --> Completed
    Trial completion
    |
    MammaPrint®
    19d
    Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study. (PubMed, Int J Cancer)
    Approximately one-third of patients who met GEP criteria and were eligible for publicly known reimbursement received a GEP. Appropriate follow-up steps and further research seem required to analyse reasons for not ordering a GEP in times of reimbursement, since GEP results help chemotherapy decision-making.
    Reimbursement • US reimbursement • Journal • Gene Expression Profile
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    19d
    Multi-regional transcriptomics reveals robust consensus subtypes beyond tumor heterogeneity of breast cancer. (PubMed, Transl Oncol)
    We established a low-ITH subtyping framework that overcomes the limitations of single-biopsy-based molecular typing. Our findings offer a novel strategy to enhance the precision of breast cancer management.
    Journal
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test • MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    21d
    S2206: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (clinicaltrials.gov)
    P3, N=3680, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2027 --> May 2032 | Trial primary completion date: May 2027 --> May 2032
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    MammaPrint®
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    28d
    Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology. (PubMed, Ann Oncol)
    BRIDGE is a biologically grounded framework for neoadjuvant BC response prediction, validated on a rich set of different patients' cohorts. Its histopathology-based version opens the door for fast and low-cost prediction in the neoadjuvant setting, upon further prospective testing and validation.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    29d
    ABBY: ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer (clinicaltrials.gov)
    P2, N=44, Recruiting, Abramson Cancer Center at Penn Medicine | N=66 --> 44
    Enrollment change • Minimal residual disease
    |
    ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Verzenio (abemaciclib) • hydroxychloroquine
    1m
    CNet-Cox for interpretable network biomarker discovery and survival risk scoring in precise breast cancer prognosis. (PubMed, NPJ Digit Med)
    Although evaluated in breast cancer, CNet-Cox is readily extensible to other diseases, molecular interaction networks and time-to-event endpoints, providing a generalizable tool for digital pathology and precision oncology. Overall, our comprehensive downstream analyses highlight that CNet-Cox offers a novel network-aware survival model for systematically discovering connected biomarkers and delivering scalable, precise and interpretable risk prediction.
    Journal
    |
    MammaPrint®
    1m
    Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer (Agendia Press Release)
    "Agendia®, Inc...today announced new data to be presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29 – June 2 in Chicago. The company will present two posters highlighting how MammaPrint® (MP) + BluePrint® (BP) provide biological insights into treatment response and help further refine therapeutic decision-making for patients with early-stage breast cancer (EBC)."
    Clinical data
    |
    MammaPrint® • BluePrint